PDG80 Healthcare Resource Utilization and Costs for Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis

Authors :: Ilaria Loperto
Raffaele Palladino
Maria Triassi
Marcello Moccia
S. Masera
L. Santoni
V Brescia Morra
Antonio Carotenuto
Source :: Value in Health. 23:S532
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: medicine.medical_specialty
business.industry
Health Policy
Multiple sclerosis
Public Health, Environmental and Occupational Health
medicine.disease
Extended interval dosing
Natalizumab
Relapsing remitting
Health care
medicine
Intensive care medicine
business
Resource utilization
medicine.drug

Full Text Access

Tools